Shawn M. Sarkaria

Learn More
Molecularly targeted therapies are transforming the care of patients with malignant gliomas, including glioblastoma, the most common malignant primary brain tumor of adults. With an arsenal of small molecule inhibitors and antibodies that target key components of the signal transduction machinery that are commonly activated in gliomas, neuro-oncologists and(More)
Acute promyelocytic leukemia (APL) is initiated by the PML-RARA (PR) fusion oncogene and has a characteristic expression profile that includes high levels of the Notch ligand Jagged-1 (JAG1). In this study, we used a series of bioinformatic, in vitro, and in vivo assays to assess the role of Notch signaling in human APL samples, and in a PML-RARA knock-in(More)
Letter to the Editor Epigenetic dysregulation represents an emerging paradigm in the pathogenesis of myeloid malignancies, and the pharmacologic targeting of pathways involved in regulating epigenetic modifications is a promising therapeutic strategy 1. Potential targets include recurrently mutated genes encoding epigenetic modifiers (e.g. DNMT3A, IDH1/2,(More)
  • 1